Manager × security

Privium Fund Management B.V. ARWR holdings history

Who else holds this security?

ARROWHEAD PHARMACEUTICALS IN · CUSIP 04280A100 · CIK 1795097

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Privium Fund Management B.V. reported 234.22K ARWR (shares), valued at $19.09M, or 3.51% of its reported non-derivative portfolio. Filed 2026-08-07.

Verify history & sources
Portfolio weight and quantity history
Reported portfolio weight
3.51%
Shares
234.22K
234,222
Reported value
$19.09M
USD

Shares decreased 36.17%; reported value decreased 17.02%, and weight changed -1.28 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20263.51%234,222SEC filingFiled Aug 7, 2026
Q1 20264.79%366,936SEC filingFiled May 5, 2026
Q4 20254.87%398,204SEC filingFiled Feb 3, 2026
Q3 20252.94%473,951SEC filingFiled Nov 4, 2025
Q2 20252.13%612,214SEC filingFiled Jul 30, 2025
Q1 20252.09%629,214SEC filingFiled May 9, 2025
Q4 20241.62%380,586SEC filingFiled Feb 11, 2025
Q3 20241.61%333,356SEC filingFiled Nov 1, 2024
Q2 20241.85%286,936SEC filingFiled Aug 1, 2024
Q1 20242.09%273,936SEC filingFiled Apr 30, 2024
Q4 20232.37%273,936SEC filingFiled Feb 26, 2024Amended
Q3 20232.07%259,036SEC filingFiled Nov 6, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20232.07%259,036$6.96MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing
Filed Nov 6, 2023
Q4 20232.37%273,936$8.49MShares increased 5.75%; reported value increased 22.05%, and weight changed +0.30 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Feb 26, 2024
Q1 20242.09%273,936$7.83MShares unchanged; reported value decreased 7.77%, and weight changed -0.28 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Apr 30, 2024
Q2 20241.85%286,936$7.24MShares increased 4.75%; reported value decreased 7.63%, and weight changed -0.24 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Aug 1, 2024
Q3 20241.61%333,356$6.46MShares increased 16.18%; reported value decreased 10.77%, and weight changed -0.24 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Nov 1, 2024
Q4 20241.62%380,586$7.16MShares increased 14.17%; reported value increased 10.81%, and weight changed +0.01 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Feb 11, 2025
Q1 20252.09%629,214$8.02MShares increased 65.33%; reported value increased 12.04%, and weight changed +0.47 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed May 9, 2025
Q2 20252.13%612,214$9.85MShares decreased 2.70%; reported value increased 22.88%, and weight changed +0.04 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Jul 30, 2025
Q3 20252.94%473,951$16.35MShares decreased 22.58%; reported value increased 65.95%, and weight changed +0.81 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Nov 4, 2025
Q4 20254.87%398,204$26.44MShares decreased 15.98%; reported value increased 61.73%, and weight changed +1.93 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Feb 3, 2026
Q1 20264.79%366,936$23.01MShares decreased 7.85%; reported value decreased 12.97%, and weight changed -0.08 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed May 5, 2026
Q2 20263.51%234,222$19.09MShares decreased 36.17%; reported value decreased 17.02%, and weight changed -1.28 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Aug 7, 2026
Privium Fund Management B.V. · ARROWHEAD PHARMACEUTICALS IN

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1795097","quarter":"2026Q2","cusip":"04280A100"}

get_institutional_manager_history
{"cik":"1795097","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.